Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROTEUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Dec 2023 Planned End Date changed from 7 Apr 2027 to 19 Jul 2029.
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2022 Planned number of patients changed from 2400 to 2500.